Mixed cryoglobulinemia associated with chronic HCV infection in the era of modern antiviral therapy: Can the problem be considered solved?
Main Article Content
Abstract
Mixed cryoglobulinemia is the most common extrahepatic manifestation of chronic HCV infection. The disease can occur both asymptomatically and in the form of systemic vasculitis with a wide range of clinical manifestations.
The development of cryoglobulinemia is based on relatively benign lymphoproliferation, which, as pathological clones increase and their malignancy can lead to the appearance of B-cell non-Hodgkin's lymphomas. The new treatment of HCV infection with direct acting antivirals allows to achieve an increase in the rate of virus elimination. However, the clinical and, especially, immunological responses associated with the disappearance of cryoglobulins, as well as the normalization of the rheumatoid factor and C4 complement components, were significantly weaker compared to the virological response. Recently, it became known about the possible positive dynamics of these parameters in the future course, but the timing and volume of such observations are clearly insufficient. The persistence of elevated rheumatoid factor values, hypocomplementemia, and, especially, cryoglobulinemia after achieving a sustained virologic response as a result of antiviral therapy raises a number of serious questions relevant for clinical practice. Among the main issues are how often and how quickly normalization of these immunological disorders is possible? What are the consequences of their persistence? Under what conditions is it appropriate to consider alternative approaches to antiviral therapy and to use immunobiological drugs aimed at suppressing B-lymphocyte proliferation?
These problems, as well as some aspects of the pathogenesis, clinical course, and treatment of extrahepatic manifestations of chronic HCV infection based on virus-induced lymphoproliferation are discussed in this literature review.
Keywords:
chronic HCV infection, mixed cryoglobulinemia, cryoglobulinemic vasculitis, direct acting antivirals
Article Details
How to Cite
ML, Zubkin et al.
Mixed cryoglobulinemia associated with chronic HCV infection in the era of modern antiviral therapy: Can the problem be considered solved?.
Medical Research Archives, [S.l.], v. 8, n. 7, july 2020.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/2172>. Date accessed: 23 apr. 2024.
doi: https://doi.org/10.18103/mra.v8i7.2172.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Adinolfi LE, Zampino R, Restivo L, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20(13):3410-3417.doi: 10.3748/wjg.v20.i13.3410 [PubMed:24707124]
2. Antonelli A, Ferri C, Ferrari SM, et al. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009;5(1):26-34. doi: 10.1038/ncpendmet1027 [PubMed: 19079271]
3. Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Gastroenterol. 2015;7(3):327-343. doi: 10.4254/wjh.v7.i3.327 [PubMed: 25848462]
4. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495-503. doi: 10.1136/gutjnl-2014-308163 [PubMed: 25398770]
5. Mao XR, Zhang LT, Chen H, et al. Possible factors affecting thyroid dysfunction in hepatitis C virus-infected untreated patients. Exp Ther Med. 2014;8(1):133-140. doi:10.3892/etm.2014.1709 [PubMed: 24944611]
6. Maruyama S, Koda M, Oyake N, et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol. 2013;58(1):11-15. doi: 10.1016/j.jhep.2012.07.045 [PubMed: 22889957]
7. Engels EA, Chatterjee N, Cerhan JR, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer 2004;111(1):76–80. doi:10.1002/ijc.20021 [PubMed: 15185346]
8. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297(18):2010–2017. doi: 10.1001/jama.297.18.2010 [PubMed: 17488966]
9. Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006;131(6):1879-1886. doi: 10.1053/j.gastro.2006.09.019 [PubMed: 17087949]
10. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775-788. doi: 10.1016/0002-9343(74)90852-3 [PubMed: 4216269]
11. Ghetie D, Mehraban N, Sibley CH. Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances. Rheum Dis Clin North Am. 2015;41(1):93-108. doi: 10.1016/j.rdc.2014.09.008 [PubMed: 25399942]
12. Dammacco F, Racanelli V, Russi S, Sansonno D. The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review. Clin Exp Med. 2016;16(3):233-242. doi: 10.1007/s10238-016-0410-9 [PubMed: 26935415]
13. Bunchorntavakul C, Mitraniy R, Reddy KR. Advances in HCV and cryoglobulinemic vasculitis in the era of DAAs: Are weat the end of the road? J Clin Exp Hepatol. 2018;8(1):81-94. doi: 10.1016 / j.jceh.2017.11.012 [PubMed: 29743799]
14. Negro F, Forton D, Craxì A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345-1360. doi: 10.1053/j.gastro.2015.08.035 [PubMed: 26319013]
15. Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75(10):1777-1782. doi: 10.1136/annrheumdis-2015-208339 [PubMed: 26567178]
16. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369(11):1035-1045. doi: 10.1056/NEJMra1208642 [PubMed: 24024840]
17. Aguiar MF, Faria-Janes AL, Garcia-Brandes GI, et al. Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients. Ann Hepatol. 2019;18(5):685-692. doi: 10.1016/j.aohep.2019.04.010 [PubMed: 31167733]
18. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology. 2002;36(4Pt1):978-985. doi: 10.1053/jhep.2002.35620 [PubMed: 12297847]
19. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002; 55(1):4-13. doi: 10.1136/jcp.55.1.4 [PubMed: 11825916]
20. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int. 2009;76(8):818-824. doi: 10.1038/ki.2009.247 [PubMed: 19606079]
21. Sene D, Ghillani-Dalbin P, Thibault V, et al. Long-term course of mixed cryoglobulinemia In patients infected with hepatitis C virus. J Rheumatol. 2004;31(11):2199-2206. [PubMed: 15517633]
22. Dammacco F, Lauletta G, Russi S, et al. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med. 2019;19(1):1-21. doi: 10.1007/s10238-018-0536-z [PubMed: 30430284]
23. Chen CL, Huang JY, Wang CH, et al. Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. Nat Commun. 2017;8:13882. doi: 10.1038/ncomms13882. [PubMed: 28067225]
24. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med. 2004;117(1):10-13. doi: 10.1016/j.amjmed.2004.01.023 [PubMed:15210382]
25. Zignego AL, Macchia D, Monti M, et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol. 1992;15(3):382-386. doi: 10.1016/0168-8278(92)90073-x [PubMed: 1332999]
26. Roque Afonso AM, Jiang J, Penin F, et al. Nonrandom distribution of hepatitis C virus quasispecies In plasma and peripheral blood mononuclear cell subsets. J Virol. 1999;73(11):9213-9221. [PubMed: 10516029]
27. Russi S, Vincenti A, Vinella A, et al. CD5/CD20 expression on circulating B cells in HCV-related chronic hepatitis and mixed cryoglobulinemia. Eur J Intern Med. 2019;66:48-56. doi: 10.1016/j.ejim.2019.05.016 [PubMed: 31126779]
28. Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology. 1997; 25(5):1237-1244. doi: 10.1002/hep.510250529 [PubMed: 9141444]
29. Lysenko L.V., Gordovskaya N.B., Korotchaeva Y.V. Diagnosis and treatment of HBV- and HCV-associated nephritis, incl. nephritis with cryoglobulin vasculitis. National Clinical Recommendations for Treatment of Glomerulonephritis. /ed.by E.Shilov clin. recommendations collection. - M. “Bely veter”, 2015; 229-247. (In Russ.)
30. Fabrizi F, Martin P, Cacoub P, et al. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16(12):1815-1827. doi: 10.1517/14656566.2015.1066333 [PubMed: 26161511]
31. Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: A review. J Adv Res. 2017;8(2):89-97. doi: 10.1016/j.jare.2016.07.005 [PubMed: 28149645]
32. Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia Vasculitis. The American Journal of Medicine. 2015;128(9):950-955. doi: 10.1016/j.amjmed.2015.02.017 [PubMed: 25837517]
33. Terrier B, Semoun O, Saadoun D, Sene D, et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63(6):1748-1757. doi: 10.1002/art.30319 [PubMed: 21400476]
34. Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med. 2005;165(1):101-105. doi: 10.1001/archinte.165.1.101 [PubMed: 15642884]
35. Dаmmacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343-353. doi: 10.1182/blood-2009-10-245878 [PubMed: 20308602]
36. Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemicvasculitis: triple/dual antiviral treatment and/or rituximab? Ann Rheum Dis. 2014;73(9):e58. doi: 10.1136/annrheumdis-2014-205997 [PubMed: 24925837]
37. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-334. doi: 10.1182/blood-2009-10-248518 [PubMed: 20439619]
38. Saadoun D, Landau DA, Calabrese LH, et al. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford). 2007; 46(8):1234-1242. doi: 10.1093/rheumatology/kem132 [PubMed: 17566058]
39. Gragnani L, Fognani E, Piluso A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015;61(4):1145-1153. doi: 10.1002/hep.27623 [PubMed: 25431357]
40. Obrișca B, Jurubița R, Sorohan B, et al. Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review. Clin Rheumatol. 2019;38(12):3677-3687. doi: 10.1007/s10067-019-04625-y [PubMed: 31172367]
41. Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmun Rev. 2015;14(10):889-896. doi: 10.1016/j.autrev.2015.05.013 [PubMed: 26031898]
42. Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63(11):1634-1639. doi; 10.1097/00007890-199706150-00017 [PubMed: 9197359]
43. Cheng Z, Zhou B, Shi X, et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin Med J (Engl). 2014;127(7):1206-1210. [PubMed: 24709167]
44. Stehman-Breen C, Alpers C, Fleet WP, et al. Focal segmental sclerosis among patients infected with HCV. Nephron. 1999;81(1):37-40. doi: 10.1159/000045243 [PubMed: 9884417]
45. Mazzaro C, Dal Maso L, Quartuccio L, et al. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol. 2018;111(2):107-114. [PubMed: 29465371]
46. Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N: Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology. 2017;65(5):1770-1771. doi: 10.1002/hep.28981 [PubMed: 27943361]
47. Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63(2):408-417. doi: 10.1002/hep.28297 [PubMed: 26474537]
48. Emeri JS, Kuczynski M, La D, et al. Treatment of hepatitis C associated mixed cryoglobulinemia with direct acting antiviral therapy. J Hepatol. 2016;64(2):779. doi:10.1016/S0168-8278(16)01520-8
49. Zubkin ML, Abdurakhmanov DT, Sagalova OI, et al. Persistent mixed cryoglobulinemia after successful antiviral treatment of chronic hepatitis C virus infection: what's the next? Scand J Gastroenterol. 2018;53(7):883-884. doi: 10.1080/00365521.2018.1477988 [PubMed: 29966445]
50. Sollima S, Milazzo L, Peri AM, et al. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford). 2016;55(11):2084-2085doi: 10.1093/rheumatology/kew268 [PubMed: 27338085]
51. Santoriello D, Pullela NK, Uday KA, et al. Persistent hepatitis C virus-associated cryoglobulinemic glomerulonephritis in patients successfully treated with direct-acting antiviral therapy. Kidney Int Rep. 2018;3(4):985-990. doi: 10.1016/j.ekir.2018.03.016 [PubMed: 29988995]
52. Boglione L, Cusato J, Pinna SM, et al. Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. Arch Virol. 2018;163(4):961-967. doi: 10.1007/s00705-017-3684-7 [PubMed: 29318374]
53. Degasperi E., Aghemo A., Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis. 2017;21(3):631-643. doi: 10.1016/j.cld.2017.03.015 [PubMed: 28689598]
54. Ramos-Casals M, Zignego AL, Ferri C, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66(6):1282-1299. doi: 10.1016/j.jhep.2017.02.010 [PubMed: 28219772]
55. Gragnani L, Visentini M, Fognani E, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64(5):1473–1482. https://doi.org/10.1002/hep.28753 [PubMed: 27483451]
56. Bonacci M, Lens S, Londono MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15(4):575-583.e1. doi: 10.1016/j.cgh.2016.09.158 [PubMed: 27725289]
57. Bonacci M, Lens S, Marino Z, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterology. 2018;155(2):311-315. doi.org/10.1053/j.gastro.2018.04.024 [PubMed: 29705529]
58. Stubbs A., Kowal1 C., Askari A., et al. Achieving Sustained Viral Remission in Patients with Chronic HCV Infection and Cryoglobulinemic Vasculitis Does Not Always Correlate with Normalization of the Serologic Markers. J Clin Cell Immunol. 2018;9(5):562. doi:10.4172/2155-9899.1000562
59. Kim IG, Frolova NF, Volodina EV, et al. Successful treatment and long-term monitoring of patient with cryoglobulinemic vasculitis associated with chronic HCV infection. Clinical observations. Rus. Nephrology and dialysis.2019;4:450-457. doi:10.28996/2618-9801
60. Sollima S, Milazzo L, Vassalini P, et al. Recurrence of mixed cryoglobulinaemia vasculitis following influenza vaccination despite clearance of hepatitis C virus infection. Clin Exp Reumatol. 2018;11(2):161-162. [PubMed: 29185964]
61. Visentini M, Quartuccio L, Del Padre M, et al. Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer. Rheumatology (Oxford). 2018;57(10):1870-1871. doi: 10.1093/rheumatology/key157 [PubMed: 29868896]
62. Ghosn M, Palmer MB, Najem CE, et al. New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy
Clin Nephrol. 2017; 87(5):261-266. doi: 10.5414/CN109019 [PubMed: 28332476]
63. Comarmond C, Garrido M, Pol S. Direct acting antiviral therapy restores immune tolerance to patients with hepatitis C virus induced cryoglobulinemia vasculitis. Gastroenterology. 2017;152(8): 2052-2062. doi: 10.1053/j.gastro.2017.02.037 [PubMed: 28274850]
64. Landau D-A, Saadoun D, Halfon Ph, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum. 2008;58(2):604-611. doi: 10.1002/art.23305 [PubMed: 18240235]
65. Del Padre M, Todi L, Mitrevski M et al. Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia. Blood. 2017;130(1):35-38. doi: 10.1182/blood-2017-03-77128 [PubMed: 28507081]
66. Sang A, Niu H, Cullen J et al. Activation of rheumatoid factor-specific B cells is antigen dependent and occurs preferentially outside of germinal centers in the lupusprone NZM2410 mouse model. J Immunol 2014; 193(4):1609-1621. doi: 10.4049/jimmunol.1303000 [PubMed: 25015835]
67. Stine JG, Cornella S, Shah NL. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann Rheum Dis.2014;73(10):e64. doi: 10.1136/annrheumdis-2014-206180 [PMID: 25038237]
68. Giannelli F, Moscarella S, Giannini C, et al. Effect of antiviral treatment in patients With chronic HCV infection and T(14;18) translocation. Blood. 2003;102(4):1196-1201. doi: 10.1182/blood-2002-05-1537 [PubMed: 12689948]
69. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41(1):106-114. doi: 10.1002/hep.20518 [PubMed: 15619235]
70. Giannini C, Petrarca A, Monti M, et al. Association between persistent lymphatic Infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood. 2008;111(5):2943-2945. doi: 10.1182/blood-2007-09-112490 [PubMed: 18299456]
71. Chowdhury R and Tsen A. Recurrent mixed cryoglobulinemia despite sustained virologic response to treatment: a case report. Am J Kidney Dis. 2017;70(2):301-304. doi: 10.1053/j.ajkd.2017.01.041 [PubMed: 28343737]
72. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490-1495. doi: 10.1056/NEJM199211193272104 [PubMed: 1383822]
73. Cacoub P, Fabiani FL, Musset L, et al. Mixed cryoglobulinemia and hepatitis C virus. Am J Med. 1994;96(2):124-132. doi: 10.1016/0002-9343(94)90132-5 [PubMed: 7509124]
74. Horcajada JP, Garcia-Bengoechea M, Cilla G, et al. Mixed cryoglobulinaemia in patients with chronic hepatitis C infection: prevalence, significance and relationship with different viral genotypes. Ann Med. 1999;31(5):352-358. doi: 10.3109/07853899908995902 [PubMed: 10574508]
75. Hartmann H, Schott P, Polzien F, et al. Cryoglobulinemia in chronic hepatitis C virus infection: prevalence, clinical manifestations, response to interferon treatment and analysis of cryoprecipitates. Z Gastroenterol. 1995;33(11):643-650. [PubMed: 8600660]
76. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355-374. doi: 10.1016/j.semarthrit.2003.10.001 [PubMed: 15190522]
77. Sultanik P, Klotz C, Brault P, et al. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood. 2015;125(15):2446-1447. doi: 10.1182/blood-2014-12-618652 [PubMed: 25858892]
78. Carrier P, Jaccard A, Jacques J, et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int. 2015;35(10):2222-2227. doi: 10.1111/liv.12897 [PubMed: 26104059]
79. Rossotti R, Travi G, Pazzi A, et al. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol. 2015;62(1):234–237. doi: 10.1016/j.jhep.2014.09.031 [PubMed: 25285757]
80. Lim LY, La D, Cserti-Gazdewich CM, Shah H. Lymphoma remission by interferon-free HCV eradication without chemotherapy. ACG Case Rep J. 2015;3(1):69-70. doi: 10.14309/crj.2015.104 [PubMed: 26504885]
81. Persico M, Aglitti A, Aghemo A, et al. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther. 2018 Jun;47(12):1705-1712. doi: 10.1111/apt.14685. [PMID: 29722439]
82. Merli M, Carli G, Arcaini L, Visco C. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J Gastroenterol. 2016; 22(38):8447-8458. doi: 10.3748/wjg.v22.i38.8447 [PubMed: 27784957]
83. Visentini M, Fiorilli M, Casato M. From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals? Expert Rev Hematol. 2017 Aug;10(8):719-727. doi: 10.1080/17474086.2017.1349607 [PMID: 28675071]
84. Alric L, Besson C, Lapidus N, et al. Antiviral treatment of HCV-infected patients with B-cell non-Hodgkin lymphoma. PLoS One. 2016;11(10):e0162965. doi: 10.1371/journal.pone.0162965 [PubMed: 27749916]
85. Tsutsumi Y, Nakayama C, Kamada K, et al. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann Hematol. 2017;96(12):2057-2061. doi: 10.1007/s00277-017-3129-0 [PubMed: 28939993]
86. Cornella SL, Stine JG, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med. 2015;127(4):413-7. doi:10.1080/00325481.2015.1021660 [PMID: 25746436]
87. Tasleem S, Sood GK. Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy. J Clin Transl Hepatol. 2015;3(2):134-139. doi:10.14218/JCTH.2015.00011 [PMID: 26357640]
2. Antonelli A, Ferri C, Ferrari SM, et al. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009;5(1):26-34. doi: 10.1038/ncpendmet1027 [PubMed: 19079271]
3. Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Gastroenterol. 2015;7(3):327-343. doi: 10.4254/wjh.v7.i3.327 [PubMed: 25848462]
4. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495-503. doi: 10.1136/gutjnl-2014-308163 [PubMed: 25398770]
5. Mao XR, Zhang LT, Chen H, et al. Possible factors affecting thyroid dysfunction in hepatitis C virus-infected untreated patients. Exp Ther Med. 2014;8(1):133-140. doi:10.3892/etm.2014.1709 [PubMed: 24944611]
6. Maruyama S, Koda M, Oyake N, et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol. 2013;58(1):11-15. doi: 10.1016/j.jhep.2012.07.045 [PubMed: 22889957]
7. Engels EA, Chatterjee N, Cerhan JR, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer 2004;111(1):76–80. doi:10.1002/ijc.20021 [PubMed: 15185346]
8. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297(18):2010–2017. doi: 10.1001/jama.297.18.2010 [PubMed: 17488966]
9. Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006;131(6):1879-1886. doi: 10.1053/j.gastro.2006.09.019 [PubMed: 17087949]
10. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775-788. doi: 10.1016/0002-9343(74)90852-3 [PubMed: 4216269]
11. Ghetie D, Mehraban N, Sibley CH. Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances. Rheum Dis Clin North Am. 2015;41(1):93-108. doi: 10.1016/j.rdc.2014.09.008 [PubMed: 25399942]
12. Dammacco F, Racanelli V, Russi S, Sansonno D. The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review. Clin Exp Med. 2016;16(3):233-242. doi: 10.1007/s10238-016-0410-9 [PubMed: 26935415]
13. Bunchorntavakul C, Mitraniy R, Reddy KR. Advances in HCV and cryoglobulinemic vasculitis in the era of DAAs: Are weat the end of the road? J Clin Exp Hepatol. 2018;8(1):81-94. doi: 10.1016 / j.jceh.2017.11.012 [PubMed: 29743799]
14. Negro F, Forton D, Craxì A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345-1360. doi: 10.1053/j.gastro.2015.08.035 [PubMed: 26319013]
15. Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75(10):1777-1782. doi: 10.1136/annrheumdis-2015-208339 [PubMed: 26567178]
16. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369(11):1035-1045. doi: 10.1056/NEJMra1208642 [PubMed: 24024840]
17. Aguiar MF, Faria-Janes AL, Garcia-Brandes GI, et al. Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients. Ann Hepatol. 2019;18(5):685-692. doi: 10.1016/j.aohep.2019.04.010 [PubMed: 31167733]
18. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology. 2002;36(4Pt1):978-985. doi: 10.1053/jhep.2002.35620 [PubMed: 12297847]
19. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002; 55(1):4-13. doi: 10.1136/jcp.55.1.4 [PubMed: 11825916]
20. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int. 2009;76(8):818-824. doi: 10.1038/ki.2009.247 [PubMed: 19606079]
21. Sene D, Ghillani-Dalbin P, Thibault V, et al. Long-term course of mixed cryoglobulinemia In patients infected with hepatitis C virus. J Rheumatol. 2004;31(11):2199-2206. [PubMed: 15517633]
22. Dammacco F, Lauletta G, Russi S, et al. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med. 2019;19(1):1-21. doi: 10.1007/s10238-018-0536-z [PubMed: 30430284]
23. Chen CL, Huang JY, Wang CH, et al. Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. Nat Commun. 2017;8:13882. doi: 10.1038/ncomms13882. [PubMed: 28067225]
24. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med. 2004;117(1):10-13. doi: 10.1016/j.amjmed.2004.01.023 [PubMed:15210382]
25. Zignego AL, Macchia D, Monti M, et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol. 1992;15(3):382-386. doi: 10.1016/0168-8278(92)90073-x [PubMed: 1332999]
26. Roque Afonso AM, Jiang J, Penin F, et al. Nonrandom distribution of hepatitis C virus quasispecies In plasma and peripheral blood mononuclear cell subsets. J Virol. 1999;73(11):9213-9221. [PubMed: 10516029]
27. Russi S, Vincenti A, Vinella A, et al. CD5/CD20 expression on circulating B cells in HCV-related chronic hepatitis and mixed cryoglobulinemia. Eur J Intern Med. 2019;66:48-56. doi: 10.1016/j.ejim.2019.05.016 [PubMed: 31126779]
28. Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology. 1997; 25(5):1237-1244. doi: 10.1002/hep.510250529 [PubMed: 9141444]
29. Lysenko L.V., Gordovskaya N.B., Korotchaeva Y.V. Diagnosis and treatment of HBV- and HCV-associated nephritis, incl. nephritis with cryoglobulin vasculitis. National Clinical Recommendations for Treatment of Glomerulonephritis. /ed.by E.Shilov clin. recommendations collection. - M. “Bely veter”, 2015; 229-247. (In Russ.)
30. Fabrizi F, Martin P, Cacoub P, et al. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16(12):1815-1827. doi: 10.1517/14656566.2015.1066333 [PubMed: 26161511]
31. Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: A review. J Adv Res. 2017;8(2):89-97. doi: 10.1016/j.jare.2016.07.005 [PubMed: 28149645]
32. Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia Vasculitis. The American Journal of Medicine. 2015;128(9):950-955. doi: 10.1016/j.amjmed.2015.02.017 [PubMed: 25837517]
33. Terrier B, Semoun O, Saadoun D, Sene D, et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63(6):1748-1757. doi: 10.1002/art.30319 [PubMed: 21400476]
34. Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med. 2005;165(1):101-105. doi: 10.1001/archinte.165.1.101 [PubMed: 15642884]
35. Dаmmacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343-353. doi: 10.1182/blood-2009-10-245878 [PubMed: 20308602]
36. Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemicvasculitis: triple/dual antiviral treatment and/or rituximab? Ann Rheum Dis. 2014;73(9):e58. doi: 10.1136/annrheumdis-2014-205997 [PubMed: 24925837]
37. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-334. doi: 10.1182/blood-2009-10-248518 [PubMed: 20439619]
38. Saadoun D, Landau DA, Calabrese LH, et al. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford). 2007; 46(8):1234-1242. doi: 10.1093/rheumatology/kem132 [PubMed: 17566058]
39. Gragnani L, Fognani E, Piluso A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015;61(4):1145-1153. doi: 10.1002/hep.27623 [PubMed: 25431357]
40. Obrișca B, Jurubița R, Sorohan B, et al. Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review. Clin Rheumatol. 2019;38(12):3677-3687. doi: 10.1007/s10067-019-04625-y [PubMed: 31172367]
41. Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmun Rev. 2015;14(10):889-896. doi: 10.1016/j.autrev.2015.05.013 [PubMed: 26031898]
42. Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63(11):1634-1639. doi; 10.1097/00007890-199706150-00017 [PubMed: 9197359]
43. Cheng Z, Zhou B, Shi X, et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin Med J (Engl). 2014;127(7):1206-1210. [PubMed: 24709167]
44. Stehman-Breen C, Alpers C, Fleet WP, et al. Focal segmental sclerosis among patients infected with HCV. Nephron. 1999;81(1):37-40. doi: 10.1159/000045243 [PubMed: 9884417]
45. Mazzaro C, Dal Maso L, Quartuccio L, et al. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol. 2018;111(2):107-114. [PubMed: 29465371]
46. Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N: Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology. 2017;65(5):1770-1771. doi: 10.1002/hep.28981 [PubMed: 27943361]
47. Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63(2):408-417. doi: 10.1002/hep.28297 [PubMed: 26474537]
48. Emeri JS, Kuczynski M, La D, et al. Treatment of hepatitis C associated mixed cryoglobulinemia with direct acting antiviral therapy. J Hepatol. 2016;64(2):779. doi:10.1016/S0168-8278(16)01520-8
49. Zubkin ML, Abdurakhmanov DT, Sagalova OI, et al. Persistent mixed cryoglobulinemia after successful antiviral treatment of chronic hepatitis C virus infection: what's the next? Scand J Gastroenterol. 2018;53(7):883-884. doi: 10.1080/00365521.2018.1477988 [PubMed: 29966445]
50. Sollima S, Milazzo L, Peri AM, et al. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford). 2016;55(11):2084-2085doi: 10.1093/rheumatology/kew268 [PubMed: 27338085]
51. Santoriello D, Pullela NK, Uday KA, et al. Persistent hepatitis C virus-associated cryoglobulinemic glomerulonephritis in patients successfully treated with direct-acting antiviral therapy. Kidney Int Rep. 2018;3(4):985-990. doi: 10.1016/j.ekir.2018.03.016 [PubMed: 29988995]
52. Boglione L, Cusato J, Pinna SM, et al. Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. Arch Virol. 2018;163(4):961-967. doi: 10.1007/s00705-017-3684-7 [PubMed: 29318374]
53. Degasperi E., Aghemo A., Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis. 2017;21(3):631-643. doi: 10.1016/j.cld.2017.03.015 [PubMed: 28689598]
54. Ramos-Casals M, Zignego AL, Ferri C, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66(6):1282-1299. doi: 10.1016/j.jhep.2017.02.010 [PubMed: 28219772]
55. Gragnani L, Visentini M, Fognani E, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64(5):1473–1482. https://doi.org/10.1002/hep.28753 [PubMed: 27483451]
56. Bonacci M, Lens S, Londono MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15(4):575-583.e1. doi: 10.1016/j.cgh.2016.09.158 [PubMed: 27725289]
57. Bonacci M, Lens S, Marino Z, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterology. 2018;155(2):311-315. doi.org/10.1053/j.gastro.2018.04.024 [PubMed: 29705529]
58. Stubbs A., Kowal1 C., Askari A., et al. Achieving Sustained Viral Remission in Patients with Chronic HCV Infection and Cryoglobulinemic Vasculitis Does Not Always Correlate with Normalization of the Serologic Markers. J Clin Cell Immunol. 2018;9(5):562. doi:10.4172/2155-9899.1000562
59. Kim IG, Frolova NF, Volodina EV, et al. Successful treatment and long-term monitoring of patient with cryoglobulinemic vasculitis associated with chronic HCV infection. Clinical observations. Rus. Nephrology and dialysis.2019;4:450-457. doi:10.28996/2618-9801
60. Sollima S, Milazzo L, Vassalini P, et al. Recurrence of mixed cryoglobulinaemia vasculitis following influenza vaccination despite clearance of hepatitis C virus infection. Clin Exp Reumatol. 2018;11(2):161-162. [PubMed: 29185964]
61. Visentini M, Quartuccio L, Del Padre M, et al. Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer. Rheumatology (Oxford). 2018;57(10):1870-1871. doi: 10.1093/rheumatology/key157 [PubMed: 29868896]
62. Ghosn M, Palmer MB, Najem CE, et al. New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy
Clin Nephrol. 2017; 87(5):261-266. doi: 10.5414/CN109019 [PubMed: 28332476]
63. Comarmond C, Garrido M, Pol S. Direct acting antiviral therapy restores immune tolerance to patients with hepatitis C virus induced cryoglobulinemia vasculitis. Gastroenterology. 2017;152(8): 2052-2062. doi: 10.1053/j.gastro.2017.02.037 [PubMed: 28274850]
64. Landau D-A, Saadoun D, Halfon Ph, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum. 2008;58(2):604-611. doi: 10.1002/art.23305 [PubMed: 18240235]
65. Del Padre M, Todi L, Mitrevski M et al. Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia. Blood. 2017;130(1):35-38. doi: 10.1182/blood-2017-03-77128 [PubMed: 28507081]
66. Sang A, Niu H, Cullen J et al. Activation of rheumatoid factor-specific B cells is antigen dependent and occurs preferentially outside of germinal centers in the lupusprone NZM2410 mouse model. J Immunol 2014; 193(4):1609-1621. doi: 10.4049/jimmunol.1303000 [PubMed: 25015835]
67. Stine JG, Cornella S, Shah NL. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann Rheum Dis.2014;73(10):e64. doi: 10.1136/annrheumdis-2014-206180 [PMID: 25038237]
68. Giannelli F, Moscarella S, Giannini C, et al. Effect of antiviral treatment in patients With chronic HCV infection and T(14;18) translocation. Blood. 2003;102(4):1196-1201. doi: 10.1182/blood-2002-05-1537 [PubMed: 12689948]
69. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41(1):106-114. doi: 10.1002/hep.20518 [PubMed: 15619235]
70. Giannini C, Petrarca A, Monti M, et al. Association between persistent lymphatic Infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood. 2008;111(5):2943-2945. doi: 10.1182/blood-2007-09-112490 [PubMed: 18299456]
71. Chowdhury R and Tsen A. Recurrent mixed cryoglobulinemia despite sustained virologic response to treatment: a case report. Am J Kidney Dis. 2017;70(2):301-304. doi: 10.1053/j.ajkd.2017.01.041 [PubMed: 28343737]
72. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490-1495. doi: 10.1056/NEJM199211193272104 [PubMed: 1383822]
73. Cacoub P, Fabiani FL, Musset L, et al. Mixed cryoglobulinemia and hepatitis C virus. Am J Med. 1994;96(2):124-132. doi: 10.1016/0002-9343(94)90132-5 [PubMed: 7509124]
74. Horcajada JP, Garcia-Bengoechea M, Cilla G, et al. Mixed cryoglobulinaemia in patients with chronic hepatitis C infection: prevalence, significance and relationship with different viral genotypes. Ann Med. 1999;31(5):352-358. doi: 10.3109/07853899908995902 [PubMed: 10574508]
75. Hartmann H, Schott P, Polzien F, et al. Cryoglobulinemia in chronic hepatitis C virus infection: prevalence, clinical manifestations, response to interferon treatment and analysis of cryoprecipitates. Z Gastroenterol. 1995;33(11):643-650. [PubMed: 8600660]
76. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355-374. doi: 10.1016/j.semarthrit.2003.10.001 [PubMed: 15190522]
77. Sultanik P, Klotz C, Brault P, et al. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood. 2015;125(15):2446-1447. doi: 10.1182/blood-2014-12-618652 [PubMed: 25858892]
78. Carrier P, Jaccard A, Jacques J, et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int. 2015;35(10):2222-2227. doi: 10.1111/liv.12897 [PubMed: 26104059]
79. Rossotti R, Travi G, Pazzi A, et al. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol. 2015;62(1):234–237. doi: 10.1016/j.jhep.2014.09.031 [PubMed: 25285757]
80. Lim LY, La D, Cserti-Gazdewich CM, Shah H. Lymphoma remission by interferon-free HCV eradication without chemotherapy. ACG Case Rep J. 2015;3(1):69-70. doi: 10.14309/crj.2015.104 [PubMed: 26504885]
81. Persico M, Aglitti A, Aghemo A, et al. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther. 2018 Jun;47(12):1705-1712. doi: 10.1111/apt.14685. [PMID: 29722439]
82. Merli M, Carli G, Arcaini L, Visco C. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J Gastroenterol. 2016; 22(38):8447-8458. doi: 10.3748/wjg.v22.i38.8447 [PubMed: 27784957]
83. Visentini M, Fiorilli M, Casato M. From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals? Expert Rev Hematol. 2017 Aug;10(8):719-727. doi: 10.1080/17474086.2017.1349607 [PMID: 28675071]
84. Alric L, Besson C, Lapidus N, et al. Antiviral treatment of HCV-infected patients with B-cell non-Hodgkin lymphoma. PLoS One. 2016;11(10):e0162965. doi: 10.1371/journal.pone.0162965 [PubMed: 27749916]
85. Tsutsumi Y, Nakayama C, Kamada K, et al. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann Hematol. 2017;96(12):2057-2061. doi: 10.1007/s00277-017-3129-0 [PubMed: 28939993]
86. Cornella SL, Stine JG, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med. 2015;127(4):413-7. doi:10.1080/00325481.2015.1021660 [PMID: 25746436]
87. Tasleem S, Sood GK. Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy. J Clin Transl Hepatol. 2015;3(2):134-139. doi:10.14218/JCTH.2015.00011 [PMID: 26357640]